Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David Eastwood is active.

Publication


Featured researches published by David Eastwood.


Journal of Immunology | 2007

“Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics

Richard Stebbings; Lucy Findlay; Cherry Edwards; David Eastwood; Chris Bird; David North; Yogesh Mistry; Paula Dilger; Emily C. Liefooghe; Isabelle Cludts; Bernard Fox; Gill Tarrant; Jane Robinson; Tony Meager; Carl Dolman; Susan J. Thorpe; Adrian Bristow; Meenu Wadhwa; Robin Thorpe; Stephen Poole

The CD28-specific mAb TGN1412 rapidly caused a life-threatening “cytokine storm” in all six healthy volunteers in the Phase I clinical trial of this superagonist, signaling a failure of preclinical safety testing. We report novel in vitro procedures in which TGN1412, immobilized in various ways, is presented to human white blood cells in a manner that stimulates the striking release of cytokines and profound lymphocyte proliferation that occurred in vivo in humans. The novel procedures would have predicted the toxicity of this superagonist and are now being applied to emerging immunotherapeutics and to other therapeutics that have the potential to act upon the immune system. Data from these novel procedures, along with data from in vitro and in vivo studies in nonhuman primates, suggest that the dose of TGN1412 given to human volunteers was close to the maximum immunostimulatory dose and that TGN1412 is not a superagonist in nonhuman primates.


Journal of Virology | 2014

Effect of Formaldehyde Inactivation on Poliovirus

Thomas Wilton; Glynis Dunn; David Eastwood; Philip D. Minor; Javier Martin

ABSTRACT Inactivated polio vaccines, which have been used in many countries for more than 50 years, are produced by treating live poliovirus (PV) with formaldehyde. However, the molecular mechanisms underlying virus inactivation are not well understood. Infection by PV is initiated by virus binding to specific cell receptors, which results in viral particles undergoing sequential conformational changes that generate altered structural forms (135S and 80S particles) and leads to virus cell entry. We have analyzed the ability of inactivated PV to bind to the human poliovirus receptor (hPVR) using various techniques such as ultracentrifugation, fluorescence-activated cell sorting flow cytometry and real-time reverse transcription-PCR (RT-PCR). The results showed that although retaining the ability to bind to hPVR, inactivated PV bound less efficiently in comparison to live PV. We also found that inactivated PV showed resistance to structural conversion in vitro, as judged by measuring changes in antigenicity, the ability to bind to hPVR, and viral RNA release at high temperature. Furthermore, viral RNA from inactivated PV was shown to be modified, since cDNA yields obtained by RT-PCR amplification were severely reduced and no infectious virus was recovered after RNA transfection into susceptible cells. IMPORTANCE This study represents a novel insight into the molecular mechanisms responsible for poliovirus inactivation. We show that inactivation with formaldehyde has an effect on early steps of viral replication as it reduces the ability of PV to bind to hPVR, decreases the sensitivity of PV to convert to 135S particles, and abolishes the infectivity of its viral RNA. These changes are likely responsible for the loss of infectivity shown by PV following inactivation. Techniques used in this study represent new approaches for the characterization of inactivated PV products and could be useful in developing improved methods for the production and quality control testing of inactivated polio vaccines. Measuring the antigenicity, capsid stability, and RNA integrity of inactivated PV samples could help establishing the optimal balance between the loss of infectivity and the preservation of virus antigenicity during inactivation.


Journal of Immunology | 2012

Antibody C region influences TGN1412-like functional activity in vitro.

Christina Ball; Bernard Fox; Simon E. Hufton; Giles Sharp; Stephen Poole; Richard Stebbings; David Eastwood; Lucy Findlay; Paul Parren; Robin Thorpe; Adrian Bristow; Susan J. Thorpe

The unexpected outcome of the clinical trial of the superagonistic CD28 mAb TGN1412 (IgG4κ) continues to stimulate interest. We show that TGN1412 binds similarly to human and cynomolgus macaque FcγR, eliminating the possibility that differences in Fc-mediated interactions with FcγR contributed to the failure of preclinical testing in macaques to predict toxicity in humans. The influence of the Fc domain and C region structure on the in vitro functional activity of TGN1412 was investigated using F(ab′)2 and Fab fragments derived from TGN1412 recovered from the trial and recombinant TGN1412 subclass variants and mutants. Superagonistic activity, as measured by cytokine release and proliferation, was assessed by exposing PBMCs to immobilized mAbs/fragments or to aqueous mAbs/fragments in the presence of HUVEC monolayers. Removing the Fc generally curtailed or abolished PBMC activation. However, eliminating detectable FcγR-binding of the IgG4 by mutation (L235E) did not abrogate activity. Stabilizing the “wild-type” IgG4 hinge (S228P) enhanced activity without increasing FcγR binding, which could only partially be explained by inhibition of Fab arm–exchange. Subclass switching the IgG4 mAb to IgG1 decreased activity, whereas switching to IgG2 markedly increased activity. We conclude that the C region strongly influences in vitro CD28-mediated superagonistic signaling. Superagonism requires an intact Fc, as shown by the absence of activity of TGN1412 Fab and F(ab′)2 fragments, but, notably, appears to be relatively independent of FcγR-binding properties. We propose that the Fc, potentially through restricting flexibility, maintains a favorable V region conformation to allow superagonistic activity. These findings have important implications for Ab design strategies.


Journal of Immunological Methods | 2015

Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.

Sandrine Vessillier; David Eastwood; Bernard Fox; Jean Sathish; S. Sethu; T. Dougall; Susan J. Thorpe; Robin Thorpe; R. Stebbings

The therapeutic monoclonal antibody (mAb) TGN1412 (anti-CD28 superagonist) caused near-fatal cytokine release syndrome (CRS) in all six volunteers during a phase-I clinical trial. Several cytokine release assays (CRAs) with reported predictivity for TGN1412-induced CRS have since been developed for the preclinical safety testing of new therapeutic mAbs. The whole blood (WB) CRA is the most widely used, but its sensitivity for TGN1412-like cytokine release was recently criticized. In a comparative study, using group size required for 90% power with 5% significance as a measure of sensitivity, we found that WB and 10% (v/v) WB CRAs were the least sensitive for TGN1412 as these required the largest group sizes (n = 52 and 79, respectively). In contrast, the peripheral blood mononuclear cell (PBMC) solid phase (SP) CRA was the most sensitive for TGN1412 as it required the smallest group size (n = 4). Similarly, the PBMC SP CRA was more sensitive than the WB CRA for muromonab-CD3 (anti-CD3) which stimulates TGN1412-like cytokine release (n = 4 and 4519, respectively). Conversely, the WB CRA was far more sensitive than the PBMC SP CRA for alemtuzumab (anti-CD52) which stimulates FcγRI-mediated cytokine release (n = 8 and 180, respectively). Investigation of potential factors contributing to the different sensitivities revealed that removal of red blood cells (RBCs) from WB permitted PBMC-like TGN1412 responses in a SP CRA, which in turn could be inhibited by the addition of the RBC membrane protein glycophorin A (GYPA); this observation likely underlies, at least in part, the poor sensitivity of WB CRA for TGN1412. The use of PBMC SP CRA for the detection of TGN1412-like cytokine release is recommended in conjunction with adequately powered group sizes for dependable preclinical safety testing of new therapeutic mAbs.


The FASEB Journal | 2015

An autologous endothelial cell:peripheral blood mononuclear cell assay that detects cytokine storm responses to biologics

Daniel M. Reed; Koralia E. Paschalaki; Richard Starke; Nura A. Mohamed; Giles Sharp; Bernard Fox; David Eastwood; Adrian Bristow; Christina Ball; Sandrine Vessillier; Trevor T. Hansel; Susan J. Thorpe; Anna M. Randi; Richard Stebbings; Jane A. Mitchell

There is an urgent unmet need for human tissue bioassays to predict cytokine storm responses to biologics. Current bioassays that detect cytokine storm responses in vitro rely on endothelial cells, usually from umbilical veins or cell lines, cocultured with freshly isolated peripheral blood mononuclear cells (PBMCs) from healthy adult volunteers. These assays therefore comprise cells from 2 separate donors and carry the disadvantage of mismatched tissues and lack the advantage of personalized medicine. Current assays also do not fully delineate mild (such as Campath) and severe (such as TGN1412) cytokine storm‐inducing drugs. Here, we report a novel bioassay where endothelial cells grown from stem cells in the peripheral blood (blood outgrowth endothelial cells) and PBMCs from the same donor can be used to create an autologous coculture bioassay that responds by releasing a plethora of cytokines to authentic TGN1412 but only modestly to Campath and not to control antibodies such as Herceptin, Avastin, and Arzerra. This assay performed better than the traditional mixed donor assay in terms of cytokine release to TGN1412 and, thus, we suggest provides significant advancement and a definitive system by which biologics can be tested and paves the way for personalized medicine.—Reed, D. M., Paschalaki, K. E., Starke, R. D., Mohamed, N. A., Sharp, G., Fox, B., Eastwood, D., Bristow, A., Ball, C., Vessillier, S., Hansel, T. T., Thorpe, S. J., Randi, A. M., Stebbings, R., Mitchell, J. A. An autologous endothelial cell:peripheral blood mononuclear cell assay that detects cytokine storm responses to biologics. FASEB J. 29, 2595‐2602 (2015). www.fasebj.org


Journal of Virology | 2014

Correction for Wilton et al., Effect of Formaldehyde Inactivation on Poliovirus

Thomas Wilton; Glynis Dunn; David Eastwood; Philip D. Minor; Javier Martin

Thomas Wilton,* Glynis Dunn, David Eastwood, Philip D. Minor, Javier Martin Divisions of Virology, and Biotherapeutics, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom Volume 88, no. 20, p. 11955–11964. Page 11955: The byline should appear as shown above. Page 11955, column 2, shaded box: The corresponding author e-mail and present address footnote should read “t.a.wilton@ btinternet.com” and “*Present address: Thomas Wilton, Crucell Holland B.V., Leiden, Netherlands.”


Journal of Immunological Methods | 2010

Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412.

Lucy Findlay; David Eastwood; Richard Stebbings; Giles Sharp; Yogesh Mistry; Christina Ball; John Hood; Robin Thorpe; Stephen Poole


Journal of Immunological Methods | 2011

Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy.

Lucy Findlay; David Eastwood; Christina Ball; C. Jane Robinson; Chris Bird; Meenu Wadhwa; Susan J. Thorpe; Robin Thorpe; Richard Stebbings; Stephen Poole


Cytokine | 2011

Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture.

Lucy Findlay; Giles Sharp; Bernard Fox; Christina Ball; C. Jane Robinson; Christopher Bird; Richard Stebbings; David Eastwood; Meenu Wadhwa; Stephen Poole; Robin Thorpe; Susan J. Thorpe


Cytokine | 2013

How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response

Susan J. Thorpe; Richard Stebbings; Lucy Findlay; David Eastwood; Stephen Poole; Robin Thorpe

Collaboration


Dive into the David Eastwood's collaboration.

Top Co-Authors

Avatar

Richard Stebbings

National Institute for Biological Standards and Control

View shared research outputs
Top Co-Authors

Avatar

Susan J. Thorpe

National Institute for Biological Standards and Control

View shared research outputs
Top Co-Authors

Avatar

Robin Thorpe

National Institute for Biological Standards and Control

View shared research outputs
Top Co-Authors

Avatar

Lucy Findlay

National Institute for Biological Standards and Control

View shared research outputs
Top Co-Authors

Avatar

Stephen Poole

National Institute for Biological Standards and Control

View shared research outputs
Top Co-Authors

Avatar

Bernard Fox

National Institute for Biological Standards and Control

View shared research outputs
Top Co-Authors

Avatar

Christina Ball

National Institute for Biological Standards and Control

View shared research outputs
Top Co-Authors

Avatar

Giles Sharp

National Institute for Biological Standards and Control

View shared research outputs
Top Co-Authors

Avatar

Sandrine Vessillier

National Institute for Biological Standards and Control

View shared research outputs
Top Co-Authors

Avatar

Adrian Bristow

National Institute for Biological Standards and Control

View shared research outputs
Researchain Logo
Decentralizing Knowledge